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Abstract: In this study, the putative correlation between the molecular mobility of a polymer and
the ball milling drug amorphization kinetics (i.e., time to reach full drug amorphization, ta) was
studied using different grades of dextran (Dex) and polyvinylpyrrolidone (PVP) and the two model
drugs indomethacin (IND) and chloramphenicol (CAP). In general, IND had lower ta values than
CAP, indicating that IND amorphized faster than CAP in the presence of the polymers. In addition,
an increase in polymer molecular weight (Mw) also led to an increase in ta for all systems investigated
up to a critical Mw for each polymer, which was in line with an increase of the glass transition
temperature (Tg) up to the critical Mw of each polymer. Hence, the increase in ta seemed to correlate
well with the Tg/Mw of the polymers, which indicates that the polymers’ molecular mobility had an
influence on the drug amorphization kinetics during ball milling.
Keywords: amorphous; solid dispersion; ball-milling; milling time; amorphization kinetics
1. Introduction
The use of the amorphous form is one of the most promising approaches to overcoming the
solubility challenge presented by the increasing amount of poorly soluble drugs [1–3]. Since amorphous
solids are disordered and thus in a higher energy state compared to their crystalline counterparts [1],
they are thermodynamically unstable and tend to crystallize during storage. Hence, stabilization of
the amorphous form, especially through incorporation in a polymeric carrier to create a so-called
amorphous solid dispersion (ASD), have been widely investigated [3]. Since the drug itself may be
miscible or even soluble in the polymer, such an ASD can in theory be thermodynamically stable if the
drug loading is below its equilibrium solubility in the polymer at the storage conditions [4]. In contrast,
drug loadings above the equilibrium solubility will eventually lead to the crystallization of the drug [5].
For these thermodynamically unstable systems, other factors that contribute to the stabilization of
the amorphous drug in an ASD become more relevant, such as potential intermolecular interactions
between the drug and polymer [6], or a decrease in molecular mobility [7].
In this regard, it has been shown that increasing the polymer chain length/molecular weight (Mw)
increases the physical stability of an ASD of indomethacin (IND) in polyvinylpyrrolidone (PVP) as a
result of overall reduced molecular mobility [8]. Furthermore, the Mw of the polymer has also been
shown to affect the dissolution rate and performance of the drug from an ASD. Here, increasing the Mw
of PVP decreased the dissolution rate of celecoxib compared to PVP with lower Mw [9]. Nevertheless,
the ASDs with the lower Mw PVP did not display the best overall dissolution performance (area under
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the dissolution-time curve) due to an inferior precipitation-inhibiting effect compared to the ASDs
containing higher Mw PVP.
In order to incorporate the drug into the polymer network, several methods are described in
the literature, including ball milling, quench cooling and spray drying. Ball milling is often used in
early-stage research as it can be performed at a small scale and does not require any heat or solvents [10].
On the other hand, the method requires a milling time long enough for the incorporation of the drug
into the polymer network to achieve full amorphization, which may be as long as 2 h when using an
oscillatory ball mill or even 8 h when using a planetary mill [10,11]. However, little is known about
the influence of polymer Mw on the ball-milling time required to reach full drug amorphization (ta).
In this study, it is hypothesized that the incorporation of a drug into the polymer is dependent on the
molecular mobility of the polymer. Hence, polymers with higher Mw may require longer milling times
to obtain an ASD during milling. In this regard, it has been shown that the relationship between the
increasing glass-transition temperature (Tg) and the increasing Mw of a polymer only applies up to
a critical Mw, above which the Tg does not increase further [12,13]. Since the Tg/Mw of a polymer
is also indirectly a measure of the molecular mobility of the polymer, this study aims to investigate
the putative correlation between the molecular mobility (Tg/Mw) of a polymer and the ball-milling
amorphization kinetics (ta) of different grades of dextran and PVP, and the two model drugs IND and
chloramphenicol (CAP).
2. Materials and Methods
2.1. Materials
Dextrans of different Mw (kDa) (Dex 1, Dex 1.5, Dex 3.5, Dex 5, Dex 10, Dex 12, Dex 40, Dex 70
and Dex 500) were kindly supplied by Pharmacosmos A/S (Holbaek, Denmark), and PVPs of different
Mw (K12, K17, K30 and K90) were kindly supplied by BASF (Ludwigshafen, Germany). PVP K60 and
chloramphenicol (CAP) were sourced from Sigma Aldrich (St. Louis, MO, USA) and indomethacin
(IND) was sourced from Fagron (Copenhagen, Denmark).
2.2. Differential Scanning Calorimetry
To determine the Tg of the different grades of PVP, a Discovery differential scanning calorimeter
(DSC) from TA Instruments Inc. (New Castle, DE, USA) was used. Samples (2–4 mg) were analysed
in TA Instruments Tzero aluminium hermetic pans with a perforated lid under 50 mL/min nitrogen
gas flow using modulated temperature DSC (mDSC). The samples were heated from 5–200 ◦C using
a heating rate of 2 ◦C/min with a modulation amplitude of 0.212 ◦C over a period of 40 s. The Tg
(midpoint) was determined using the TA Instruments TRIOS software (version 4.1.1).
2.3. Ball Milling
The time to reach full drug amorphization (ta) was studied using an oscillatory ball mill (Mixer
mill MM400, Retsch GmbH & Co., Haan, Germany), which was placed in a cold room (5 ◦C). Physical
mixtures of drug and polymer (1000 mg) were placed in 25 mL jars containing two 12 mm stainless
steel ball bearings (Retsch GmbH & Co., Haan, Germany) and milled at a frequency of 30 Hz.
The investigated drug-polymer ratios were 10:90 w/w and 50:50 w/w for mixtures containing dextrans
and PVP, respectively. In order to obtain homogeneous mixtures, the drug-polymer powder mixtures
were mixed without the ball bearings for 5 min (0 min sample). Subsequently, the ball bearings were
added to the jars and samples of approximately 10 mg were collected at predetermined time points,
from 0–60 min. Furthermore, both IND and CAP were milled without polymer to evaluate their
amorphization kinetics against the drug-polymer mixtures.
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2.4. X-Ray Powder Diffraction
The samples collected from ball milling were analysed using X-ray powder diffractometry (XRPD)
with an X’Pert Pro diffractometer from PANalytical (Almelo, the Netherlands) in order to evaluate
whether they were X-ray amorphous. The diffractometer operated in reflection mode with the use
of CuKα radiation (1.54187 Å), with the acceleration voltage and current set to 45 kV and 40 mA,
respectively. Samples were scanned from 5 to 30◦ 2θ on aluminum sample holders with a scan speed
of 0.067◦ 2θ/s and a step size of 0.026◦. Results were analyzed using the X’Pert Data Viewer software
(version 1.2, PANalytical, Almelo, the Netherlands). The amorphousness of the samples in this study
was investigated solely using XRPD, which does not provide information on the homogeneity of the
sample, i.e., whether a homogeneous single-phase amorphous solid dispersion has been created after
the applied ta. Hence, the time ta refers to the samples being X-ray amorphous.
3. Results
It has previously been shown that the Tg of dextrans increases with increasing Mw up to around
40 kDa, after which a further increase in Mw did not result in a significant further increase in the Tg [13].
Similarly, the Tg of PVP only increased with increasing Mw up to around 360 kDa (see Table 1 and
Figure 1).
Table 1. The polymer molecular weight (Mw) and corresponding glass-transition temperature (Tg) for
dextrans (Dex) and polyvinylpyrrolidone (PVP) and their influence on the ball milling time to reach
full drug amorphization (ta) for both chloramphenicol (CAP) and indomethacin (IND).
Compound Mw (kDa) Tg (◦C)
ta (min)
CAP IND
Dex 1 1.0 a 151.8 ± 0.2 c 10.0 7.5
Dex 1.5 1.6 a 162.4 ± 1.1 c 15.0 10.0
Dex 3.5 3.7 a 194.8 ± 0.4 c 22.5 15.0
Dex 5 5.2 a 204.4 ± 0.8 c 22.5 20.0
Dex 10 9.6 a 212.8 ± 0.9 c 30.0 25.0
Dex 12 11.6 a 216.9 ± 0.3 c 30.0 30.0
Dex 40 39.6 a 223.2 ± 0.0 c 45.0 45.0
Dex 70 64.6 a 224.0 ± 0.6 c 52.5 45.0
Dex 500 544.3 a 225.8 ± 0.8 c 60.0 45.0
PVP K12 2.5 b 104.8 ± 0.9 20.0 15.0
PVP K17 9.0 b 142.1 ± 0.7 20.0 15.0
PVP K30 49 b 162.5 ± 0.2 25.0 17.5
PVP K60 360 b 178.9 ± 0.6 35.0 22.5
PVP K90 1250 b 178.5 ± 0.2 45.0 25.0
a Average Mw (Mn) provided from Pharmacosmos, b Average Mw (Mn) provided from BASF, c Data from [13].
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Figure 1. Correlation between the Tg (◦C) and the Mw (kDa) for (a) different dextran grades and
(b) different PVP grades. The Tg values for the different dextran grades were obtained from [13].
Pharmaceutics 2020, 12, 483 4 of 6
The pure drugs were milled in order to investigate their behaviour upon milling for 60 min. It was
found that pure IND fully amorphized after 60 min of milling (ta = 60 min). Hence, the drug can
be prepared in its amorphous form without a carrier. On the other hand, pure CAP does not fully
amorphize even after 60 min of milling, which was evident in the remaining crystalline diffractions in
the XRPD diffractograms (data not shown). CAP is therefore not able to amorphize on its own under
these conditions.
The amorphization kinetics upon milling were investigated for the different drug-polymer
systems. The ta was characterized as the first time point where no Bragg peaks were visible in the XRPD
diffractograms. Table 1 summarizes the ta values for the different systems, and two representative
examples for the amorphization kinetics are shown in Figure 2. Figure 2a illustrates that IND fully
amorphized in the presence of Dex 40 after 45 min of milling, as indicated by the lack of Bragg peaks
in the diffractogram. Figure 2b illustrates that it was also possible to obtain an ASD containing CAP
and PVP K60 with a ta of 35 min.
For a better visualization, the obtained ta values presented in Table 1 are illustrated in Figures 3
and 4 for the various grades of dextrans and PVP, respectively. In general, IND had lower ta values
than CAP, indicating that IND amorphized faster than CAP in the presence of the polymers. This is in
line with the findings from the milling of the pure drugs, where IND could be amorphized on its own.
In addition, an increase in polymer Mw also led to an increase in ta. The fastest amorphization kinetics
were obtained for Dex 1 and PVP K12 (i.e., the polymers with the lowest Mw). With the increasing Mw
of the polymers, the subsequent increase in ta is most pronounced for dextrans grades below 40 kDa
(Dex 40) and PVP grades below 360 kDa (PVP K60). Furthermore, the presence of the polymers allowed
CAP to become amorphous and reduced the ta of IND compared to milling the drugs on their own.
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Figure 2. X-ray powder diffractometry (XRPD) diffractograms showing the decrease in crystallinity
over time for a mixture of IND and Dex 40 (10:90 w/w) (a) and a mixture of CAP and PVP K60 (50:50
w/w) (b). The ta is marked with a red circle.
When comparing Figure 1 with Figures 3 and 4, it can be seen that an increase in Mw affects both
the Tg of the polymer and the ta in a similar fashion. Furthermore, the increase of both ta and Tg is
most pronounced for lower polymer Mw, and less pronounced after the critical polymer Mw is reached.
Hence, this finding indicates that the polym r Mw (i.e., molecular mobility) appears to influence the
amorphization kinetics, and hence the ta. In thi regard, it is important to emphas ze that it has been
shown that the polymer Mw does not influence the equilibrium solubility of the drug in the polymer at
ambient temperature [14]. On the other hand, it has been shown that an ASD comprising the drug
IND together with PVP of a higher Mw (K30) showed increased physical stability as a result of overall
reduced molecular mobility compared to an ASD with PVP of lower Mw (K12) [8]. In other words,
whilst a higher Mw is more efficient at preventing crystallization, it also requires longer milling times
to achieve a fully amorphous solid dispersion.
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Finally, it should be noted that, apart from the Tg/Mw of the polymer, there are potentially other
factors contributing to the overall amorphization kinetics. This study showed for example that the
good glass former IND showed faster amo phization kinetics tha e p or glass fo mer CAP when
being milled together with a given p ymer. It is also k own that the polymer Mw does not influence
the equilibrium sol bility of the drug in the polymer [14]. Nevertheless, in light of the equilibrium
solubility of the drug in the polymer, it would be interesting to investigate how different drug loadings
would impact th amorphization kin tics. In this context, mol cular interactions b tween the drug
and the polymer, the stre gth f these interactions a d the fi al Tg of t e for ed ASD all potentially
contribute to the amorphization kinetics during milling. Lastly, the prese c of water in a polymer
significantly impacts its properties, as water acts as a plasticizer [15], lowering the polymer’s Tg
and increasing its mobility, but also reducing the equilibrium solubility of the drug in the polymeric
carrier [16]. Hence, gi n that mos polym rs are hygroscopic, the impact of water represents another
critical parameter to be investigated in future studies.
4. Conclusions
In summary, this study found a correlation between the polymer Tg/Mw and ball-milling
amorphization kinetics. The findings support our original hypothesis that increasing polymer Mw will
increase the ta, probably as a consequence of decreased molecular mobility.
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